SCHEMBL3369947

SCHEMBL3369947

CCOC(=O)C(Cc1ccc(OCCc2csc(-c3ccc(C(C)C)cc3)n2)cc1C)OCC

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.40
PPARA Q07869 4/20 0.40
PPARG P37231 3/20 0.40
MAPT P10636 7/20 0.39
TP53 P04637 5/20 0.39
LMNA P02545 4/20 0.38
PPARD Q03181 1/20 0.37
PTPN2 P17706 1/20 0.36
PTPN1 P18031 1/20 0.36
KDM4E B2RXH2 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3371423 0.93 PPARG (0.43) POLBPPARAPPARGMAPTTP53
SCHEMBL3371470 0.92 PPARA (0.39) POLBPPARAPPARGMAPTTP53
SCHEMBL3370758 0.92 TP53 (0.48) POLBMAPTTP53LMNAKDM4E
SCHEMBL3373660 0.85 MAPT (0.48) POLBPPARAPPARGMAPTTP53
SCHEMBL3368818 0.85 PPARA (0.42) POLBPPARAPPARGPPARDKDM4E
SCHEMBL3375211 0.84 PPARG (0.46) PPARAPPARGMAPTTP53LMNA
SCHEMBL3375399 0.82 ALDH1A1 (0.47) PPARAPPARGMAPTTP53PTPN2
SCHEMBL3374361 0.81 TP53 (0.38) POLBPPARAPPARGMAPTTP53
SCHEMBL3370206 0.81 ALDH1A1 (0.41) PPARAPPARGMAPTTP53LMNA
SCHEMBL3370967 0.79 PPARG (0.49) PPARAPPARGMAPTTP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537091-B1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS HOFFMANN LA ROCHE (CH) 2010-10-06 EP disclosed
EP-1537091-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2005-06-08 EP disclosed
US-6809110-B2 NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID HOFFMANN-LA ROCHE INC. 2004-10-26 US disclosed
US-20040110807-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-10 US disclosed
WO-2004020420-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110807-A1 Thiazole derivatives SLC5A1, GPR119, INSR POLB 4773/4885PPARA 287/4885PPARG 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.